Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.57 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.48 |
| ▸ | SMC2 | O95347 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.47 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570251 | 1.00 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2MAP2K5 | |
| SCHEMBL29541623 | 1.00 | MAP2K1 (0.71) | MAP2K1MAP2K2ABCB11NQO2MAP2K5 | |
| SCHEMBL388476 | 0.93 | MAP2K1 (0.69) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL390605 | 0.90 | MAP2K1 (0.61) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL393664 | 0.89 | MAP2K1 (0.56) | MAP2K1MAP2K2ABCB11NQO2SMC2 | |
| SCHEMBL2363113 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL391795 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL391362 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2ABCB11NQO2MAP2K5 | |
| SCHEMBL391796 | 0.88 | MAP2K1 (0.56) | MAP2K1MAP2K2MAP2K5 | |
| SCHEMBL391889 | 0.87 | MAP2K1 (0.58) | MAP2K1MAP2K2ABCB11NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893065-B2 | mitogen activated protein kinase inhibitors; 4-(2-Fluoro-4-(methylthio)phenylamino)-N-(2-hydroxyethoxy)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide; used in the treatment of hyperproliferative diseases, such as cancer and inflammation in mammals | ARRAY BIOPHARMA INC. (US) | 2011-02-22 | — | — | US | claimed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| US-20100004247-A1 | COMBINATION COMPRISING A MEK INHIBITOR AND AN AURORA KINASE INHIBITOR 188 | ASTRAZENECA AB (SE) | 2010-01-07 | — | — | US | claimed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | claimed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
| WO-2008120004-A1 | COMBINATION OF A MEK- INHIBITOR AND A B-RAF INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | claimed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | claimed |
| EP-1922307-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035672-A1 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | GSK3B, GSK3A, WNT3A | MAP2K1 7/4885MAP2K2 4/4885ABCB11 2851/4885 |
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MAP2K1 23/4885MAP2K2 19/4885ABCB11 2351/4885 |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885MAP2K2 63/4885ABCB11 2439/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAP2K1 826/4885MAP2K2 768/4885ABCB11 3686/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | MAP2K1 8/4885MAP2K2 10/4885ABCB11 2650/4885 |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | KIT, FLT1, HGF | MAP2K1 133/4885MAP2K2 136/4885ABCB11 3038/4885 |
| US-20050256123-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 82/4885MAP2K2 69/4885ABCB11 2311/4885 |
| US-20090209542-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 98/4885MAP2K2 82/4885ABCB11 2210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.